@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev
@VarunSaxena2: #TCT15: Startup's minimally invasive mitral valve repair tech shows promise in feasibility study. Article | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: 23andMe adds chapter to comeback story with $115M in funding. Report | Follow @EmilyWFierce
> Edwards ($EW) announced at TCT that 12 out of the 13 the patients that tried its Forma transcatheter tricuspid repair system on a compassionate use basis had successful implantations. "We are encouraged by our early experience with the FORMA system in which a valuable finding was that patients had positive changes in their symptoms and quality of life. We look forward to further study to learn if an isolated tricuspid transcatheter treatment can improve the prognosis for patients with severe TR." More
> Registry data presented at TCT found that left atrial appendage occlusion lowers the risk of stroke in patients with previous brain hemorrhages and atrial fibrillation. More
> A study presented at TCT was supportive of "virtual" fractional flow reserve, saying noninvasive means of conducting the cardiology measurements is a less costly means of assessment and improves patient outcomes. Virtual FFR involves use of CT scanning rather than an interventional catheter. More
Biotech News
@FierceBiotech: FierceBiotech Radio on Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand. More | Follow @FierceBiotech
@JohnCFierce: Zafgen hammered (again) as FDA clamps partial hold on PhIII obesity drug. Report | Follow @JohnCFierce
@DamianFierce: Lost in all this is that "Theranos" would have been a great name for a black metal band. | Follow @DamianFierce
> Biotech notches another $2B VC quarter, but can it last? More
> PTC's muscular dystrophy drug fails another key test with approval on the line. Article
Pharma News
@FiercePharma: India pharma sees trouble for its industry in newly negotiated TPP. More | Follow @FiercePharma
@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. News | Follow @EricPFierce
@CarlyHFierce: After FDA snub, AZ diabetes combo faces potential years-long delay. Article | Follow @CarlyHFierce
> U.K. cost watchdog gives thumbs-up to Bristol-Myers' hep C drug. Story
> FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims. Article